These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29159057)

  • 1. Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study.
    Bergsland N; Horakova D; Dwyer MG; Uher T; Vaneckova M; Tyblova M; Seidl Z; Krasensky J; Havrdova E; Zivadinov R
    Neuroimage Clin; 2018; 17():444-451. PubMed ID: 29159057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.
    Zivadinov R; Uher T; Hagemeier J; Vaneckova M; Ramasamy DP; Tyblova M; Bergsland N; Seidl Z; Dwyer MG; Krasensky J; Havrdova E; Horakova D
    Mult Scler; 2016 Nov; 22(13):1709-1718. PubMed ID: 26883943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.
    Meijboom R; York EN; Kampaite A; Harris MA; White N; Valdés Hernández MDC; Thrippleton MJ; MacDougall NJJ; Connick P; Hunt DPJ; Chandran S; Waldman AD;
    PLoS One; 2023; 18(7):e0288967. PubMed ID: 37506096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis.
    Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira A; Sastre-Garriga J; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Filippi M;
    Neurology; 2021 Mar; 96(11):e1561-e1573. PubMed ID: 33441452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep gray matter volume loss drives disability worsening in multiple sclerosis.
    Eshaghi A; Prados F; Brownlee WJ; Altmann DR; Tur C; Cardoso MJ; De Angelis F; van de Pavert SH; Cawley N; De Stefano N; Stromillo ML; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Vrenken H; Leurs CE; Killestein J; Pirpamer L; Enzinger C; Ourselin S; Wheeler-Kingshott CAMG; Chard D; Thompson AJ; Alexander DC; Barkhof F; Ciccarelli O;
    Ann Neurol; 2018 Feb; 83(2):210-222. PubMed ID: 29331092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of global and regional gray matter volume decrease in multiple sclerosis.
    Grothe M; Lotze M; Langner S; Dressel A
    J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of single-subject grey matter networks in early multiple sclerosis.
    Fleischer V; Gonzalez-Escamilla G; Pareto D; Rovira A; Sastre-Garriga J; Sowa P; Høgestøl EA; Harbo HF; Bellenberg B; Lukas C; Ruggieri S; Gasperini C; Uher T; Vaneckova M; Bittner S; Othman AE; Collorone S; Toosy AT; Meuth SG; Zipp F; Barkhof F; Ciccarelli O; Groppa S
    Brain; 2024 Jan; 147(1):135-146. PubMed ID: 37642541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.
    Hofstetter L; Naegelin Y; Filli L; Kuster P; Traud S; Smieskova R; Mueller-Lenke N; Kappos L; Gass A; Sprenger T; Penner IK; Nichols TE; Vrenken H; Barkhof F; Polman C; Radue EW; Borgwardt SJ; Bendfeldt K
    Mult Scler; 2014 Feb; 20(2):202-13. PubMed ID: 23804554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voxel-based analysis of gray matter relaxation rates shows different correlation patterns for cognitive impairment and physical disability in relapsing-remitting multiple sclerosis.
    Cassiano MT; Lanzillo R; Alfano B; Costabile T; Comerci M; Prinster A; Moccia M; Megna R; Morra VB; Quarantelli M; Brunetti A
    Neuroimage Clin; 2020; 26():102201. PubMed ID: 32062567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
    Fisher E; Nakamura K; Lee JC; You X; Sperling B; Rudick RA
    Mult Scler; 2016 Apr; 22(5):668-76. PubMed ID: 26238463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data.
    Datta S; Staewen TD; Cofield SS; Cutter GR; Lublin FD; Wolinsky JS; Narayana PA; ;
    Mult Scler Relat Disord; 2015 Mar; 4(2):124-36. PubMed ID: 25787188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
    Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
    JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
    Weeda MM; van Nederpelt DR; Twisk JWR; Brouwer I; Kuijer JPA; van Dam M; Hulst HE; Killestein J; Barkhof F; Vrenken H; Pouwels PJW
    J Neurol; 2024 Jan; 271(1):355-373. PubMed ID: 37716917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretable and Intuitive Machine Learning Approaches for Predicting Disability Progression in Relapsing-Remitting Multiple Sclerosis Based on Clinical and Gray Matter Atrophy Indicators.
    Yan Z; Shi Z; Zhu Q; Feng J; Liu Y; Li Y; Zhou F; Zhuo Z; Ding S; Wang X; Yin F; Tang Y; Lin B; Li Y
    Acad Radiol; 2024 Jul; 31(7):2910-2921. PubMed ID: 38429188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
    AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
    J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers.
    Bussas M; Grahl S; Pongratz V; Berthele A; Gasperi C; Andlauer T; Gaser C; Kirschke JS; Wiestler B; Zimmer C; Hemmer B; Mühlau M
    Mult Scler; 2022 May; 28(6):900-909. PubMed ID: 34591698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.
    Riccitelli GC; Pagani E; Rodegher M; Colombo B; Preziosa P; Falini A; Comi G; Filippi M; Rocca MA
    Mult Scler; 2019 Feb; 25(2):204-216. PubMed ID: 29173009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates.
    Rekik A; Aissi M; Rekik I; Mhiri M; Frih MA
    Brain Behav; 2022 May; 12(5):e2573. PubMed ID: 35398999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.